← Back to Search

2 for Prostate Cancer

Phase 2
Waitlist Available
Led By Allan J Pantuck, MD
Research Sponsored by Roll International Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

High concentrations of anti-oxidants in pomegranate seeds present a potential strategy to delay clinical prostate cancer progression and prolong the interval from primary treatment failure to hormonal ablation. This is a 48 month extension to the double-blind GUP-0205-1 study, to compare the effects of daily consumption of pomegranate liquid extract versus placebo on the absolute prostate-specific antigen (PSA) doubling time at the end of 12, 24, 36 and 48 months in male subjects who rolled-over from the GUP-0205-1 study.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 2Experimental Treatment1 Intervention
Group II: 1Experimental Treatment1 Intervention
Group III: 3Placebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
pomegranate juice
2014
Completed Phase 4
~320
pomegranate extract
2024
N/A
~60

Find a Location

Who is running the clinical trial?

Roll International CorporationLead Sponsor
3 Previous Clinical Trials
597 Total Patients Enrolled
2 Trials studying Prostate Cancer
213 Patients Enrolled for Prostate Cancer
Allan J Pantuck, MDPrincipal InvestigatorUniversity of California, Los Angeles
2 Previous Clinical Trials
55 Total Patients Enrolled
2 Trials studying Prostate Cancer
55 Patients Enrolled for Prostate Cancer
Arie S Belldegrun, MDPrincipal InvestigatorUniversity of California, Los Angeles
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Prostate Cancer
30 Patients Enrolled for Prostate Cancer
~11 spots leftby Nov 2025